Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mini-Tumors grown in lab could unlock colon cancer resistance secrets

NCT ID NCT05038358

Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects tumor samples from 60 patients with colorectal cancer before they receive any chemotherapy. Researchers will grow mini-tumors (organoids) in the lab to study how the immune system and tumor cells interact. The goal is to understand why 30-50% of patients do not respond to chemotherapy from the start, which could lead to better personalized treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify new markers to predict chemotherapy resistance and pave the way for personalized treatments for colorectal cancer.
What could go wrong
This is an early-stage observational study with only 60 participants. It focuses on lab research, not direct patient treatment, so benefits may take years to materialize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

colorectal adenocarcinoma, naive from neo-adjuvant chemotherapy, indication of surgical resection

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female over 18 years old. * Managed at the CHUGA for a colorectal adenocarcinoma * With an indication for immediate surgical resection as part of the care. * Patient naive from neo-adjuvant chemotherapy * Patient did not object to the CRC-ORGA-2 study Exclusion Criteria: * Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress). * Patients with positive HIV, HBV, HCV serology.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon tumor Primary tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Grenoble Alpes

    RECRUITING

    Grenoble, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.